Close

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018

Summit Therapeutics plc 
(‘Summit’ or the ’Company’)

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018

Oxford, UK, and Cambridge, MA, US, 6 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the third quarter and nine months ended 31 October 2018 on 11 December 2018.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoea and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit    
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)   +1 617 225 4455
     
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson    
     
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
   
     
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson    
     
MSL Group (US) Tel: +1 781 684 6557
Jon Siegal   summit@mslgroup.com
     
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson /   summit@consilium-comms.com
Lindsey Neville    

-END-

Summit Master_rgb_png.png